AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2884879 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201-995 (25 micrograms, subcutaneously, twice daily)
Number of subjects: 0
Study 29261533 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone (KA)
Number of subjects: 30
Study 29261533 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronate (HA)
Number of subjects: 30
Study 26947331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus palbociclib
Number of subjects: 521
Study 26947331 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant plus placebo
Number of subjects: 521
Study 25194408 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation (250 mg, three times per week for 8 weeks)
Number of subjects: 172
Study 25194408 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (saline)
Number of subjects: 172
Study 25194408 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 172
Study 21478298 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon™ 3 self‐ligating brackets (SLB)
Number of subjects: 29
Study 21478298 — intervention group
Group type: COMPARATOR
Intervention: Mini Diamond conventional ligating brackets (CLB)
Number of subjects: 29
Study 20105426 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 202
Study 20105426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 18082217 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostataplex soft gels (2 soft gels daily for 12 weeks)
Number of subjects: 92
Study 18082217 — intervention group
Group type: COMPARATOR
Intervention: Placebo soft gels (2 soft gels daily for 12 weeks)
Number of subjects: 92
Study 16632780 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler sonography in patients with colorectal liver metastases
Number of subjects: 28
Study 14705281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive academic detailing for general practitioners (GPs)
Number of subjects: 39
Study 11037850 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cloxacillin and cefixime
Number of subjects: 73
Study 11037850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 8610379 — intervention group
Group type: EXPERIMENTAL
Intervention: BT563 (10 mg/day for 12 days)
Number of subjects: 60
Study 8610379 — intervention group
Group type: COMPARATOR
Intervention: ATG (5 mg/kg/day for 7 days)
Number of subjects: 60
Study 8240460 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 2 mg E2
Number of subjects: 14
Study 8240460 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 4 mg E2
Number of subjects: 14
Study 8240460 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of 8 mg E2
Number of subjects: 14
Study 8240460 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of 0.3 mg E2
Number of subjects: 14
Study 8240460 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of E2 (overall)
Number of subjects: 14
Study 3486756 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose (SD) of 2 mg/kg intravenously
Number of subjects: 24
Study 3486756 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose (SD) of 2 mg/kg plus a 2 mg/kg/h intravenous infusion (SDI)
Number of subjects: 24
Study 30080889 — intervention group
Group type: EXPERIMENTAL
Intervention: Music listening
Number of subjects: 50
Study 30080889 — intervention group
Group type: EXPERIMENTAL
Intervention: News listening
Number of subjects: 50
Study 30080889 — intervention group
Group type: COMPARATOR
Intervention: No sound (control)
Number of subjects: 50
Study 26905956 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer co-led educational programme (8-hour group session + individual pretreatment planning session)
Number of subjects: 93
Study 26905956 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer co-led educational programme
Number of subjects: 93
Study 24434128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile Electrostatic Field (PESF) treatment in group C (T2DM with leg ulcers)
Number of subjects: 67
Study 24434128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile Electrostatic Field (PESF) treatment in group A (obese without glucose intolerance)
Number of subjects: 67
Study 24434128 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile Electrostatic Field (PESF) treatment in group B (obese intolerant to glucose)
Number of subjects: 67
Study 24434128 — intervention group
Group type: COMPARATOR
Intervention: Control group D (T2DM with leg ulcers)
Number of subjects: 67
Study 22374991 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse gastric cancer incidence among foreign-born Hispanic men
Number of subjects: 0
Study 22374991 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffuse gastric cancer incidence among U.S.-born Hispanic women
Number of subjects: 0
Study 22374991 — intervention group
Group type: COMPARATOR
Intervention: Intestinal gastric cancer incidence
Number of subjects: 0
Study 22374991 — intervention group
Group type: COMPARATOR
Intervention: Cardia and noncardia gastric cancer incidence
Number of subjects: 0
Study 22374991 — intervention group
Group type: COMPARATOR
Intervention: Noncardia and both intestinal and diffuse gastric cancer
Number of subjects: 0
Study 22374991 — intervention group
Group type: COMPARATOR
Intervention: Cardia tumors incidence among younger and middle-aged Hispanic men
Number of subjects: 0
Study 20439601 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic surfactant
Number of subjects: 208
Study 20439601 — intervention group
Group type: COMPARATOR
Intervention: nCPAP
Number of subjects: 208
Study 18328683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol (FSC(BHR) group)
Number of subjects: 466
Study 18328683 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP(BHR) group)
Number of subjects: 466
Study 18328683 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP(REF) group)
Number of subjects: 466
Study 15620775 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior approach (n=81)
Number of subjects: 127
Study 15620775 — intervention group
Group type: COMPARATOR
Intervention: Posterior approach (n=46)
Number of subjects: 127
Study 12091559 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive recovery response to the first slip
Number of subjects: 12
Study 12091559 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated exposure to slip perturbation
Number of subjects: 12
Study 12091559 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of surface condition before hand
Number of subjects: 12
Study 10361180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundic mobilization during Nissen fundoplication
Number of subjects: 50
Study 10361180 — intervention group
Group type: COMPARATOR
Intervention: No fundic mobilization during Nissen fundoplication
Number of subjects: 50
Study 10361180 — intervention group
Group type: EXPERIMENTAL
Intervention: Fundic mobilization
Number of subjects: 50
Study 10361180 — intervention group
Group type: COMPARATOR
Intervention: No fundic mobilization
Number of subjects: 50
Study 8636011 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 240 mg/m2
Number of subjects: 27
Study 8636011 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 270 mg/m2
Number of subjects: 27
Study 8636011 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel 3-h infusion
Number of subjects: 27
Study 2167727 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional interferon alpha‐2b (Intron a)
Number of subjects: 0
Study 2167727 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 381955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticrynafen, 125‐‐250 mg/day
Number of subjects: 0
Study 381955 — intervention group
Group type: COMPARATOR
Intervention: Probenecid, 0.5‐‐1.0 g/day
Number of subjects: 0
Study 381955 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticrynafen
Number of subjects: 0
Study 31926442 — intervention group
Group type: EXPERIMENTAL
Intervention: Eye movements during memory recall
Number of subjects: 140
Study 31926442 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no eye movements)
Number of subjects: 140
Study 31388297 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold depression (HADS depression score 4-7)
Number of subjects: 355
Study 31388297 — intervention group
Group type: EXPERIMENTAL
Intervention: HADS depression >8
Number of subjects: 355
Study 31388297 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (general)
Number of subjects: 355
Study 28551283 — intervention group
Group type: EXPERIMENTAL
Intervention: 30mg of dexamethasone i.v. and i.m.
Number of subjects: 119
Study 28551283 — intervention group
Group type: COMPARATOR
Intervention: No glucocorticoid (control)
Number of subjects: 119
Study 25033745 — intervention group
Group type: EXPERIMENTAL
Intervention: Warmed irrigation solutions (37 °C) in group W
Number of subjects: 60
Study 25033745 — intervention group
Group type: COMPARATOR
Intervention: Room temperature irrigation solutions (21 °C) in group R
Number of subjects: 60
Study 23281623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tool for Evaluating Research Implementation Challenges (TECH)
Number of subjects: 8
Study 21964530 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 or 5-LOX inhibitors plus chemotherapy
Number of subjects: 0
Study 21964530 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 0
Study 18205578 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined chlamydia and Pap screening offered by doctors in intervention practices
Number of subjects: 26876
Study 18205578 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (screening guidelines based on risk assessment) in control practices
Number of subjects: 26876
Study 18205578 — intervention group
Group type: COMPARATOR
Intervention: Intervention practices compared to control practices
Number of subjects: 26876
Study 16918897 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccine
Number of subjects: 0
Study 16918897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14666026 — intervention group
Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation
Number of subjects: 40
Study 14666026 — intervention group
Group type: COMPARATOR
Intervention: Uncoated extracorporeal circulation with shed blood separation
Number of subjects: 40
Study 14666026 — intervention group
Group type: COMPARATOR
Intervention: Coated extracorporeal circulation with shed blood separation
Number of subjects: 40
Study 14666026 — intervention group
Group type: COMPARATOR
Intervention: No extracorporeal circulation
Number of subjects: 40
Study 10971533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucodyne
Number of subjects: 163
Study 10971533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study 8655160 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin Regimen A - 1.0 g once weekly for 4 weeks
Number of subjects: 11
Study 8655160 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin Regimen B - 500 mg daily for 7 days
Number of subjects: 11
Study 8655160 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (both regimens)
Number of subjects: 11
Study 1513195 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusion (mean total dose 6.4 +/- 2.7 mg/kg)
Number of subjects: 40
Study 1513195 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (mean concentration 0.9 +/- 0.4%)
Number of subjects: 40
Study 6440180 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 2.5 mg
Number of subjects: 12
Study 6440180 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg
Number of subjects: 12
Study 6440180 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam 10 mg
Number of subjects: 12
Study 6440180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31399943 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intragastric balloon (IGB)
Number of subjects: 66
Study 31399943 — intervention group
Group type: COMPARATOR
Intervention: Control (no IGB)
Number of subjects: 66
Study 29368178 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-based virtual surgical planning with 3D printed pre-contoured plates (Group A)
Number of subjects: 25
Study 29368178 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of intra-operative contouring (Group B)
Number of subjects: 25
Study 26644265 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 20
Study 26644265 — intervention group
Group type: COMPARATOR
Intervention: Text4Diet
Number of subjects: 20
Study 25787196 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 280
Study 25787196 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 280
Study 23086179 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar lesions
Number of subjects: 47
Study 23086179 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 47
Study 21108021 — intervention group
Group type: EXPERIMENTAL
Intervention: Silastic® ring sleeve gastrectomy (SRSG)
Number of subjects: 65
Study 21108021 — intervention group
Group type: COMPARATOR
Intervention: Silastic® ring gastric bypass (SRGB)
Number of subjects: 65
Study 18476293 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Conservation (DC)
Number of subjects: 5472
Study 18476293 — intervention group
Group type: COMPARATOR
Intervention: Viral Suppression (VS)
Number of subjects: 5472
Study 18476293 — intervention group
Group type: EXPERIMENTAL
Intervention: DC with CD4+ cell count <350 cells/microL
Number of subjects: 5472
Study 18476293 — intervention group
Group type: EXPERIMENTAL
Intervention: DC with CD4+ cell count >=350 cells/microL
Number of subjects: 5472
Study 16571140 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant Hepatitis B virus vaccine (40 microg for HIV positive patients, 20 microg for controls)
Number of subjects: 60
Study 13679330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic screening for AAA
Number of subjects: 125000
Study 10736382 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) given without food
Number of subjects: 130
Study 10736382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 8624183 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/d of buprenorphine
Number of subjects: 225
Study 8624183 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d of methadone
Number of subjects: 225
Study 8624183 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/d of methadone
Number of subjects: 225
Study 8624183 — intervention group
Group type: COMPARATOR
Intervention: low-dose methadone
Number of subjects: 225
Study 8624183 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose methadone
Number of subjects: 225
Study 1308919 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Energy Quantitative Computed Tomography (SEQCT)
Number of subjects: 44
Study 1308919 — intervention group
Group type: COMPARATOR
Intervention: Dual Energy X‐ray Absorptiometry (DEXA)
Number of subjects: 44
Study 1308919 — intervention group
Group type: COMPARATOR
Intervention: Total Body DEXA
Number of subjects: 44
Study 2578493 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral hydroxyzine, 25 mg four times a day
Number of subjects: 0
Study 31411985 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel + ADT
Number of subjects: 0
Study 31411985 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone + ADT
Number of subjects: 0
Study 31411985 — intervention group
Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 0
Study 29663828 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led palliative care intervention integrated with anti-retroviral therapy (ART)
Number of subjects: 120
Study 29663828 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 120
Study 26392403 — intervention group
Group type: EXPERIMENTAL
Intervention: Melt-in-mouth pellets of taste-masked atomoxetine hydrochloride
Number of subjects: 10
Study 24656538 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor infusion (bolus plus 2-h infusion) and ticagrelor (180 mg) at 0.5 h (n = 6) or 1.25 h (n = 6)
Number of subjects: 12
Study 24656538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (90 mg twice daily for either 6 doses or 7 doses)
Number of subjects: 12
Study 24656538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor given before or during infusion of cangrelor
Number of subjects: 12
Study 24656538 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor during infusion of cangrelor
Number of subjects: 12
Study 22747914 — intervention group
Group type: EXPERIMENTAL
Intervention: Benefit finding intervention
Number of subjects: 0
Study 22747914 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Number of subjects: 0
Study 22747914 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified psychoeducation
Number of subjects: 0
Study 22747914 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 20920649 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-power 808-nm laser illumination
Number of subjects: 101
Study 20920649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser illumination)
Number of subjects: 101
Study 18597667 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-based learning methodology
Number of subjects: 0
Study 18597667 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching methods (implied control)
Number of subjects: 0
Study 16651318 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 185
Study 16651318 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 185
Study 12756156 — intervention group
Group type: EXPERIMENTAL
Intervention: POTS patients
Number of subjects: 25
Study 12756156 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 25
Study 10817002 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral spinal anesthesia with 8 mg of 0.5% hyperbaric bupivacaine
Number of subjects: 50
Study 10817002 — intervention group
Group type: COMPARATOR
Intervention: Combined sciatic-femoral nerve block with 25 ml of 2% mepivacaine
Number of subjects: 50
Study 8685662 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized consultation
Number of subjects: 183
Study 8685662 — intervention group
Group type: EXPERIMENTAL
Intervention: Group psychoeducation
Number of subjects: 183
Study 8685662 — intervention group
Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 183
Study 1724365 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (Trasylol)
Number of subjects: 60
Study 1724365 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6841658 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid morphine (8 and 16 mg)
Number of subjects: 32
Study 6841658 — intervention group
Group type: EXPERIMENTAL
Intervention: Deltoid methadone (10 mg)
Number of subjects: 32
Study 31332803 — intervention group
Group type: EXPERIMENTAL
Intervention: Workplace bullying
Number of subjects: 471
Study 31332803 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived burdensomeness
Number of subjects: 471
Study 31332803 — intervention group
Group type: EXPERIMENTAL
Intervention: Thwarted belongingness
Number of subjects: 471
Study 29152781 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) for 12 weeks
Number of subjects: 91
Study 29152781 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir and pibrentasvir (G/P; 300 mg/120 mg) for 16 weeks
Number of subjects: 91
Study 27819111 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretics (including doses ≥80 mg furosemide equivalent/day)
Number of subjects: 1190
Study 27819111 — intervention group
Group type: COMPARATOR
Intervention: No loop diuretics
Number of subjects: 1190
Study 24388010 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 index of reactivity (IR) tablets
Number of subjects: 509
Study 24388010 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 index of reactivity (IR) tablets
Number of subjects: 509
Study 24388010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study 22475306 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 90
Study 22475306 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE
Number of subjects: 90
Study 22475306 — intervention group
Group type: COMPARATOR
Intervention: Control (benzocaine gel)
Number of subjects: 90
Study 20447832 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG+CRT
Number of subjects: 178
Study 20447832 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 178
Study 17050549 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral cystectomy (experimental group, n=15)
Number of subjects: 32
Study 17050549 — intervention group
Group type: COMPARATOR
Intervention: Oophorectomy plus controlateral cystectomy (control group, n=17)
Number of subjects: 32
Study 17050549 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral cystectomy (experimental group)
Number of subjects: 32
Study 17050549 — intervention group
Group type: COMPARATOR
Intervention: Oophorectomy plus controlateral cystectomy (control group)
Number of subjects: 32
Study 17050549 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study 15621324 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted walking (Lokomat)
Number of subjects: 0
Study 15621324 — intervention group
Group type: COMPARATOR
Intervention: Treadmill walking
Number of subjects: 0
Study 12402450 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol aqueous solution
Number of subjects: 24
Study 12402450 — intervention group
Group type: COMPARATOR
Intervention: 0.1% timolol hydrogel
Number of subjects: 24
Study 10465182 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol 80 microg with continuous oral norethisterone 1 mg
Number of subjects: 0
Study 10465182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8652243 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepacrine chloride
Number of subjects: 30